a member of the arrestin/beta-arrestin protein family. These proteins participate in agonist-mediated desensitization of G-protein-coupled receptors. Acts as a cofactor in the beta-adrenergic receptor kinase (BARK) mediated desensitization of beta-adrenergic receptors. Expressed at high levels in the CNS and peripheral blood leukocytes. Note: This description may include information from UniProtKB.
Molecular Function: angiotensin receptor binding; protein kinase B binding; protein domain specific binding; follicle stimulating hormone receptor binding; type 2A serotonin receptor binding; alpha-1B adrenergic receptor binding; alpha-1A adrenergic receptor binding; protein binding; G-protein-coupled receptor binding; ubiquitin protein ligase binding; protein complex binding; mitogen-activated protein kinase binding; type 1 angiotensin receptor binding; protein complex scaffold; D1 dopamine receptor binding; receptor binding
Biological Process: transcription from RNA polymerase II promoter; proteasomal ubiquitin-dependent protein catabolic process; follicle-stimulating hormone signaling pathway; positive regulation of receptor internalization; protein ubiquitination; adult walking behavior; protein transport; transforming growth factor beta receptor signaling pathway; receptor internalization; negative regulation of interleukin-6 production; detection of temperature stimulus involved in sensory perception of pain; arrestin mediated desensitization of G-protein coupled receptor protein signaling pathway; platelet activation; Notch signaling pathway; negative regulation of interleukin-12 production; negative regulation of natural killer cell mediated cytotoxicity; positive regulation of synaptic transmission, dopaminergic; negative regulation of interleukin-1 beta production; negative regulation of tumor necrosis factor production; positive regulation of protein kinase B signaling cascade; positive regulation of peptidyl-tyrosine phosphorylation; G-protein coupled receptor internalization; positive regulation of protein ubiquitination; inhibition of NF-kappaB transcription factor; negative regulation of toll-like receptor signaling pathway; negative regulation of protein ubiquitination; brain development; positive regulation of calcium ion transport; blood coagulation
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.